SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 3, 2004
Progenics Pharmaceuticals, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
--------------------------- ---------- --------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
---------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
-------------
-------------------------------------------------------------
(Former name or former address, if changed since last report.)
Section 7 - Regulation FD
Item 7.01 Regulation FD Disclosure
Progenics Pharmaceuticals, Inc. today announced that it has reached the
target enrollment in the first of two pivotal phase 3 clinical trials of its
investigational drug, methylnaltrexone (MNTX) for the treatment of
opioid-induced constipation in patients with advanced medical illness (AMI). The
Company expects to announce top-line results from the 150-patient, multi-center,
double-blind, randomized, placebo-controlled phase 3 study in early 2005.
The information furnished pursuant to Item 7.01 in this Form 8-K shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liability of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 7.01 in this Form 8-K.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statement and Exhibits
(c) the following exhibits are filed with this report
Exhibit Number Description
99.1 Press release dated December 3, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ ROBERT A. MCKINNEY
-----------------------------------------
Robert A. McKinney
Vice President, Finance & Operations
Date: December 8, 2004